[Clinical evaluation of a new radiopharmaceutical agent 99mTc-mercaptoacetyltriglycine (MAG3)].
In the present clinically oriented study the authors checked the properties of 99mTc-mercaptoacetyltriglycine (MAG3), the new radiopharmaceutical for dynamic scintigraphy of the kidneys, in a group of 30 patients. They positively value particularly the high quality of visualization of the parenchyma and the urinary tract, the pharmacokinetic properties similar to those of 131I-orthoiodhippurate and the capability of representation of the kidneys with their markedly decreased function. They examined the take-up of the pharmaceutical in the liver, which is slightly more marked with the worsening tubular function and partly depends also on the length of the time interval between the preparation and administration of MAG3. No significant changes were found in the clinical and principal laboratory parameters after its administration. In conclusion, the authors point out to advantageous properties of the novel radiopharmaceutical for clinical use in our conditions.
Lepej
J
J
Klinika nukleárnej medicíny, Hematologicko-transfúzne oddelenie Fakultnej nomocnice s poliklinikou, Martin.
Altmann
P
P
Marosová
A
A
Horák
V
V
Kliment
J
J
Buchanec
J
J
Pullmann
R
R
Radakovic
M
M
Holan
J
J
Svitác
J
J
D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000000981:diagnostic imaging; D008297:Male; D009842:Oligopeptides / Q000493:pharmacokinetics / Q000494:pharmacology; D015609:Organotechnetium Compounds / Q000493:pharmacokinetics / Q000494:pharmacology; D011877:Radionuclide Imaging; D017263:Technetium Tc 99m Mertiatide
D009842:Oligopeptides; D015609:Organotechnetium Compounds; D017263:Technetium Tc 99m Mertiatide
Klinické hodnotenie nového rádiofarmaka 99mTc-merkaptoacetyltriglycínu (MAG3).